3SBio, Inc. operates as an investment holding company, which engages in the development, production, marketing, and sale of biopharmaceutical products. The company is headquartered in Shenyang, Liaoning and currently employs 6,268 full-time employees. The company went IPO on 2015-06-11. The firm's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The firm is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The firm's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The firm mainly operates its businesses in the domestic and overseas markets.
Portfolio
